Department of Hepatobiliary and Pancreatovascular Surgery, First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
Department of Hepatobiliary and Pancreatovascular Surgery, First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
Hepatobiliary Pancreat Dis Int. 2019 Aug;18(4):313-320. doi: 10.1016/j.hbpd.2019.02.003. Epub 2019 Feb 22.
Frequent recurrent hepatic metastasis after hepatic metastasectomy is a major obstacle in the treatment of colorectal liver metastasis (CRLM). We performed the present systematic review to evaluate the short- and long-term outcomes after repeat hepatectomy for recurrent CRLM and determine factors associated with survival in these patients.
An electronic search of PubMed database was undertaken to identify all relevant peer-reviewed papers published in English between January 2000 and July 2018. Hazard ratios (HR) with 95% confidence interval (95% CI) were calculated for prognostic factors of overall survival (OS).
The search yielded 34 studies comprising 3039 patients, with a median overall morbidity of 23% (range 8%-71%), mortality of 0 (range 0-6%), and 5-year OS of 42% (range 17%-73%). Pooled analysis showed that primary T3/T4 stage tumor (HR = 1.94; 95% CI: 1.04-3.63), multiple tumors (HR = 1.49; 95% CI: 1.10-2.01), largest liver lesion ≥5 cm (HR = 1.89; 95% CI: 1.11-3.23) and positive surgical margin (HR = 1.80; 95% CI: 1.09-2.97) at initial hepatectomy, and high serum level of carcinoembryonic antigen (HR = 1.87; 95% CI: 1.27-2.74), disease-free interval ≤12 months (HR = 1.34; 95% CI: 1.10-1.62), multiple tumors (HR = 1.64; 95% CI: 1.32-2.02), largest liver lesion ≥5 cm (HR = 1.85; 95% CI: 1.34-2.56), positive surgical margin (HR = 2.25; 95% CI: 1.39-3.65), presence of bilobar disease (HR = 1.62; 95% CI: 1.19-2.20), and extrahepatic metastases (HR = 1.60; 95% CI: 1.23-2.09) at repeat hepatectomy were significantly associated with poor OS.
Repeat hepatectomy is a safe and effective therapy for recurrent CRLM. Long-term outcome is predicted mainly by factors related to repeat hepatectomy.
肝转移瘤切除术后频繁出现肝转移复发是结直肠癌肝转移(CRLM)治疗的主要障碍。我们进行了这项系统评价,以评估复发性 CRLM 重复肝切除术后的短期和长期结果,并确定与这些患者生存相关的因素。
对 2000 年 1 月至 2018 年 7 月期间发表的英文同行评审论文进行了电子检索,以确定所有相关文献。使用风险比(HR)和 95%置信区间(95%CI)计算总体生存率(OS)的预后因素。
搜索结果包括 34 项研究,共 3039 例患者,总体发病率中位数为 23%(范围 8%-71%),死亡率为 0(范围 0%-6%),5 年 OS 率为 42%(范围 17%-73%)。汇总分析显示,初始肝切除时原发 T3/T4 期肿瘤(HR=1.94;95%CI:1.04-3.63)、多个肿瘤(HR=1.49;95%CI:1.10-2.01)、最大肝病变≥5cm(HR=1.89;95%CI:1.11-3.23)和阳性手术切缘(HR=1.80;95%CI:1.09-2.97)、血清癌胚抗原水平升高(HR=1.87;95%CI:1.27-2.74)、无疾病间期≤12 个月(HR=1.34;95%CI:1.10-1.62)、多个肿瘤(HR=1.64;95%CI:1.32-2.02)、最大肝病变≥5cm(HR=1.85;95%CI:1.34-2.56)、阳性手术切缘(HR=2.25;95%CI:1.39-3.65)、双侧病变(HR=1.62;95%CI:1.19-2.20)和肝外转移(HR=1.60;95%CI:1.23-2.09)与较差的 OS 显著相关。
复发性肝切除是复发性 CRLM 的一种安全有效的治疗方法。长期预后主要由与重复肝切除术相关的因素决定。